Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Am J Otolaryngol. 2020 Jul-Aug;41(4):102547. doi: 10.1016/j.amjoto.2020.102547. Epub 2020 May 17.
N-Methyladenosine (mA) is a ubiquitous RNA modification with vital roles in various cancers, but little is known about its role in papillary thyroid carcinoma (PTC), a common endocrine malignancy.
In this study, an mA RNA methylation regulator-based biomarker signature was developed for the effective prediction of prognosis in patients with PTC. The gene expression profiles of mA RNA methylation regulators and the corresponding clinical information was downloaded from The Cancer Genome Atlas (TCGA). Differentially expressed mA RNA methylation regulators between tumor and normal control samples, and correlation expression levels, clinical parameters, and outcomes were evaluated. And a prognostic signature was built using a PTC cohort from TCGA.
The expression level of HNRNPC was remarkably upregulated in tumor samples, while WTAP, RBM15, YTHDC2, YTHDC1, FTO, METTL14, METTL3, ALKBH5, KIAA1429, YTHDF1, and ZC3H13 were significantly downregulated in the cancer specimens compared with those in control samples. A three-gene prognostic signature comprising RBM15, KIAA1429, and FTO could predict overall survival in patients with PTC. In addition, the prognostic signature-based risk score was identified as an independent prognostic indicator for PTC.
We established a robust mA RNA methylation regulator-based molecular signature for predicting prognosis in patients with PTC with high accuracy; this signature might provide important guidance for therapeutic strategies.
N6-甲基腺苷（mA）是一种普遍存在的 RNA 修饰物，在各种癌症中具有重要作用，但在甲状腺乳头状癌（PTC）中，其作用知之甚少，PTC 是一种常见的内分泌恶性肿瘤。
在这项研究中，我们开发了一个基于 mA RNA 甲基化调节剂的生物标志物特征，用于有效预测 PTC 患者的预后。mA RNA 甲基化调节剂的基因表达谱和相应的临床信息从癌症基因组图谱（TCGA）中下载。评估肿瘤和正常对照样本之间差异表达的 mA RNA 甲基化调节剂，以及相关表达水平、临床参数和结果。并使用 TCGA 中的 PTC 队列构建预后签名。
HNRNPC 的表达水平在肿瘤样本中显著上调，而 WTAP、RBM15、YTHDC2、YTHDC1、FTO、METTL14、METTL3、ALKBH5、KIAA1429、YTHDF1 和 ZC3H13 在癌症样本中的表达明显低于对照样本。由 RBM15、KIAA1429 和 FTO 组成的三个基因预后签名可以预测 PTC 患者的总生存期。此外，基于预后签名的风险评分被确定为 PTC 的独立预后指标。
我们建立了一个基于 mA RNA 甲基化调节剂的可靠分子特征，用于预测 PTC 患者的预后，具有很高的准确性；该特征可能为治疗策略提供重要指导。
